联合抗病毒药物在动物模型中的视网膜毒性

Retinal toxicity of combination antiviral drugs in an animal model.

作者信息

Small G H, Peyman G A, Srinivasan A, Smith R T, Fiscella R

机构信息

Department of Ophthalmology, Eye and Ear Infirmary, University of Illinois College of Medicine at Chicago.

出版信息

Can J Ophthalmol. 1987 Oct;22(6):300-3.

PMID:3123041

Abstract

We investigated the retinal toxicity of various combinations of four antiviral agents in intravitreal injection and vitrectomy infusion solutions in the rabbit. The nontoxic concentration of each individual agent for intravitreal injection and for vitrectomy infusion has previously been described. Our results support the concept that concentrations of 200 micrograms/0.1 mL of trifluridine, 400 micrograms/0.1 mL of hydroxyacyclovir, 200 micrograms/0.1 mL of acyclovir and 30 micrograms/0.1 mL of vidarabine can be combined for intravitreal injection without toxic retinal effects. Moreover, 60 micrograms/mL of trifluridine, 20 micrograms/mL of hydroxyacyclovir, 40 micrograms/mL of acyclovir and 8 micrograms/mL of vidarabine can be combined in vitrectomy infusion solutions without retinal damage. Further study is needed to determine the full potential of such combinations.

摘要

我们研究了四种抗病毒药物的不同组合在兔玻璃体内注射和玻璃体切割灌注液中的视网膜毒性。此前已描述了每种药物用于玻璃体内注射和玻璃体切割灌注的无毒浓度。我们的结果支持以下观点：200微克/0.1毫升的三氟尿苷、400微克/0.1毫升的羟乙磺酸阿昔洛韦、200微克/0.1毫升的阿昔洛韦和30微克/0.1毫升的阿糖腺苷可以联合用于玻璃体内注射，而不会产生视网膜毒性作用。此外，60微克/毫升的三氟尿苷、20微克/毫升的羟乙磺酸阿昔洛韦、40微克/毫升的阿昔洛韦和8微克/毫升的阿糖腺苷可以联合用于玻璃体切割灌注液中，而不会造成视网膜损伤。需要进一步研究以确定此类组合的全部潜力。